遠大醫藥(00512.HK)中期純利12.03億港元 同比大幅上漲67.4%
格隆匯8月10日丨遠大醫藥(00512.HK)發佈公吿,截至2021年6月30日止六個月期間的收益約港幣45.665億元,同比上漲約40.3%。該期間公司擁有人應占年內溢利總約港幣12.025億元,同比大幅上漲約67.4%。如撇除對Telix投資的公允價值變動收益,公司擁有人應占期內溢利同比增長26.3%。基本每股盈利33.88港仙。
受益於集團盈利結構的進一步優化,以及集團深入踐行創新及壁壘藥發展戰略,並持續推動創新高壁壘與高毛利產品的銷售,期內集團的毛利率錄得約63.3%,與2020年同期毛利率62.7%比較增加了約0.6個百分點。
報吿期間,現有業務持續穩定增長,與此同時集團大力投入產品研發和佈局,投入大量資源用於在臨牀前研究、臨牀試驗、上市註冊等工作,並與多間公司合作以取得不同產品的研發、生產及商業化等權利及用於加強進一步合作,合計投入超過港幣15.3億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.